Click through this slide summary for a look at some of the more significant approvals so far for primary care.
Just shy of 3 months into the new year, the FDA has already granted a number of new drug approvals and new indications for drugs already approved. Scroll through the slides above for a look at some of the more significant recent approvals for primary care.For a quick review of last year’s approvals, go to Top 20 Primary Care Drugs Approved in 2016. SOURCESCenterWatch: 2016 FDA Approved DrugsDrugs.com: New Drug ApprovalsÂ
FDA Approves Guselkumab for Pediatric Plaque Psoriasis and Active Psoriatic Arthritis
September 30th 2025The FDA has approved guselkumab for children aged 6 years and older with moderate to severe plaque psoriasis or active psoriatic arthritis, making it the first IL-23 inhibitor authorized for pediatric use.